Comparative Pharmacology
Head-to-head clinical analysis: ACUVUE THERAVISION WITH KETOTIFEN versus LORATADINE REDIDOSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACUVUE THERAVISION WITH KETOTIFEN versus LORATADINE REDIDOSE.
ACUVUE THERAVISION WITH KETOTIFEN vs LORATADINE REDIDOSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ketotifen is a selective histamine H1-receptor antagonist and mast cell stabilizer that inhibits the release of inflammatory mediators such as histamine and leukotrienes from mast cells.
Selective peripheral H1 receptor antagonist; inhibits histamine release from mast cells.
One drop in each affected eye twice daily (approximately 8 hours apart) as needed. The lens should be removed prior to instillation and can be reinserted after at least 10 minutes.
10 mg orally once daily
None Documented
None Documented
12 hours (terminal elimination half-life; clinical context: twice-daily dosing needed for continuous effect).
Terminal elimination half-life is 8–14 hours (mean ~12 hours) for desloratadine (active metabolite); parent loratadine half-life ~3–20 hours (mean ~8 hours). Clinically, once-daily dosing maintains steady state in 5–7 days.
Renal (approximately 50% as unchanged drug, 30% as metabolites); biliary/fecal elimination accounts for <10%.
Renal (approximately 40% as metabolites), biliary/fecal (approximately 60% as metabolites). Less than 1% excreted unchanged in urine.
Category A/B
Category A/B
Antihistamine / Mast Cell Stabilizer
Antihistamine